Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Dec 3;107(1):354.
doi: 10.1093/jnci/dju354. Print 2015 Jan.

Risk-benefit profiles of women using tamoxifen for chemoprevention

Hazel B Nichols  1 , Lisa A DeRoo  2 , Daniel R Scharf  2 , Dale P Sandler  2
Affiliations

Risk-benefit profiles of women using tamoxifen for chemoprevention

Hazel B Nichols et al. J Natl Cancer Inst. .

Abstract

Background: Tamoxifen has been US Food and Drug Administration-approved for primary prevention of breast cancer since 1998 but has not been widely adopted, in part because of increased risk of serious side effects. Little is known about the risk-benefit profiles of women who use chemoprevention outside of a clinical trial. We examined characteristics associated with initiation and discontinuation of tamoxifen for primary prevention of breast cancer within a large cohort of women with a first-degree family history of breast cancer.

Methods: This research was conducted within The Sister Study, a cohort of 50884 US and Puerto Rican women age 35 to 74 years enrolled from 2003 to 2009. Eligible women were breast cancer-free at enrollment and had a sister who had been diagnosed with breast cancer. Participants reported tamoxifen use, ages started and stopped taking tamoxifen, and total duration of use at enrollment. We identified 788 tamoxifen users and 3131 nonusers matched on age and year of enrollment who had no history of contraindicating factors (stroke, transient ischemic attack, cataract, endometrial or uterine cancer). Characteristics associated with tamoxifen initiation were evaluated with multivariable conditional logistic regression. All statistical tests were two-sided.

Results: Based on published risk-benefit indices, 20% of women who used tamoxifen had insufficient evidence that the benefits of tamoxifen outweigh the risk of serious side effects. After 4.5 years, 46% of women had discontinued tamoxifen.

Conclusions: While the majority of women who used tamoxifen for primary prevention of breast cancer were likely to benefit, substantial discontinuation of tamoxifen before five years and use by women at risk of serious side effects may attenuate benefits for breast cancer prevention.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
A) Percent of tamoxifen users with a risk-benefit index (16,20) indicating no, moderate, or strong evidence that the benefits of tamoxifen for the primary prevention of breast cancer and fracture exceed the risk of serious side effects (ie, endometrial cancer, stroke, pulmonary embolism, deep vein thrombosis, and cataract). Percentages are shown overall and according to hysterectomy status, race, and age at tamoxifen initiation. B) Odds ratios (95% confidence intervals) for a favorable risk-benefit profile (moderate or strong evidence that benefits of tamoxifen outweigh the risks) according to hysterectomy status, race, and age at tamoxifen initiation. CI = confidence interval.
Figure 2.
Figure 2.
Kaplan–Meier survival curve of discontinuation before five years among women taking tamoxifen for primary prevention of breast cancer.
See this image and copyright information in PMC

Comment in

References

    1. Freedman AN, Graubard BI, Rao SR, et al. Estimates of the number of US women who could benefit from tamoxifen for breast cancer chemoprevention. J Natl Cancer Inst. 2003;95(7):526–532. - PubMed
    1. Cuzick J, Sestak I, Bonanni B, et al. Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data. Lancet. 2013;381(9880):1827–1834. - PMC - PubMed
    1. Cuzick J, Forbes J, Edwards R, et al. First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial. Lancet. 2002;360(9336):817–824. - PubMed
    1. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst. 1998;90(18):1371–1388. - PubMed
    1. Powles T, Eeles R, Ashley S, et al. Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial. Lancet. 1998;352(9122):98–101. - PubMed

Publication types

MeSH terms

Substances